The prevalence of atrial fibrillation (AF) in the United States has been projected to increase 2.5-fold by 2050 to 5.6 million individuals and was estimated at 33.5 million worldwide in 2010. [1] [2] [3] International population-based studies have identified an 18% rise in disability-adjusted life-years attributable to AF globally. 2 This growth has been attributed to several factors, including aging populations, more chronic cardiovascular disease, and increasing prevalence of AF risk factors, such as obesity. 4 However, although prior studies have provided evidence of regional differences in incidence and demographics, no in-depth data on this worldwide epidemic have been reported.
In this setting, several disease-specific, prospective observational registry programs were created to better understand AF populations, their demography, treatments, and clinical outcomes. Internationally, the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) registry enrolled patients from around the globe and culminated in a population of more than 57,000 patients recruited over the course of 5 phases in 35 countries. The largest in the United States, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) program, includes 2 phases of enrollment totaling nearly 25,000 patients. Collaboration between the programs will yield powerful insights regarding AF population characteristics globally, treatments, and outcomes among regions, and allow for investigation of phenomena too rare to explore in individual cohorts. In this analysis, we compared the baseline populations from the GARFIELD-AF and ORBIT-AF programs, including comparisons of baseline stroke and bleeding risk profiles, as well as variations in the prescribing practice for stroke prevention by region and by stroke-risk profile.
Methods
These analyses include data from all 5 enrollment cohorts of the GARFIELD-AF registry and both phases of the ORBIT-AF program. Separate data from each program are presented side-by-side for comparison.
GARFIELD-AF
GARFIELD-AF is an international prospective noninterventional registry of patients who were enrolled within 6 weeks of diagnosis of nonvalvular AF. Patients were included if they had at least 1 additional risk factor for stroke as defined by the patient's physician. This could include a CHA 2 DS 2 -VASc risk factor or an alternative characteristic that the physician felt increased the patient's risk of stroke (and was not collected). Neither treatment with stroke prevention therapy nor minimum CHADS 2 or CHA 2 DS 2 -VASc score was required for inclusion.
To reflect real-world care delivery, site makeup in GARFIELD-AF varied according to geography. For each country, delivery care patterns were assessed, and randomly selected generalist and specialty providers were invited to participate so that the balance of sites, by country, reflected local AF care. These could include primary care physicians, internal medicine, geriatricians, cardiologists, and/or neurologists.
Patient demographic, medical history, AF history, electrocardiographic and laboratory data, imaging, and medical and interventional treatments were prospectively recorded in a Web-based case report form. Patients were enrolled chronologically in 5 consecutive cohorts beginning in December 2010 with the completion of enrollment in July 2016. Follow-up will conclude in 2018, with a minimum of 2-year follow-up (for cohort 5) and a maximum of 7-year follow-up (for patients enrolled in cohort 1).
As a sensitivity analysis, the design of the GARFIELD-AF program included a retrospective cohort of patients with known AF as part of cohort 1. As in prior analyses from GARFIELD-AF, data from that retrospective cohort are not included in this analysis. The complete design and methods of the GARFIELD-AF registry have been described in detail previously. 5 All patients in GARFIELD-AF signed written informed consent, and GARFIELD-AF received regulatory approval pursuant to local policies.
ORBIT-AF
The ORBIT-AF program included 2 separate, observational US registries: ORBIT-AF I and ORBIT-AF II. The ORBIT-AF I cohort was enrolled from 2010 to 2011 and included adult patients with electrocardiographically proven AF not due to a reversible cause. Enrollment in ORBIT-II occurred between 2013 and 2016 and had additional inclusion criteria: patients either had to have a recent diagnosis of AF (b6 months) and/or they had to have recently transitioned to a non-vitamin K oral anticoagulant (NOAC; b3 months). Because of these differences in entry criteria, the 2 ORBIT-AF cohorts are presented separately here.
Patients were enrolled in each phase of ORBIT-AF from a nationally representative sample of sites providing care for patients with AF in the United States, and there was significant overlap between sites participating in ORBIT-AF I and ORBIT-AF II. They included primary care physicians, cardiologists, electrophysiologists, and neurologists. Similar clinical data were collected in each phase of ORBIT-AF: baseline demographics, medical history, vital signs, laboratory data, imaging and electrocardiographic data, AF symptoms and history, and medical and interventional therapies received. These data elements were entered into a Web-based case report form.
Complete details of the ORBIT-AF I and ORBIT-AF II registry designs have been previously described. 6, 7 Each phase of ORBIT-AF was approved separately by the Duke University institutional review board as well as by governing oversight groups pursuant to local regulations. All patients provided written informed consent.
Registry methods compared
Notable distinguishing characteristics of each registry design are shown in Table I . Importantly, GARFIELD-AF included only patients with a diagnosis of AF within 6 weeks of enrollment, whereas ORBIT-AF I enrolled patients irrespective of time since diagnosis, and ORBIT-AF II only required a recent diagnosis (b6 months) for patients not recently switched to a NOAC. The additional distinguishing characteristic of the GARFIELD-AF registry was a requirement for at least 1 investigator-defined risk factor for stroke in addition to AF-this was not required in either ORBIT-AF phase. Lastly, GARFIELD-AF excluded patients with valvular AF (as defined by local practice), whereas both ORBIT-AF registries allowed valvular and nonvalvular AF.
Patient involvement
Patients were not involved in the design, recruitment, or conduct of this analysis; however, outcomes measured by these registries are informed by previously described patient priorities. These include clinically relevant events such as stroke and major bleeding. Study burden to patients was minimized, as no additional follow-up visits or testing was performed beyond those carried out as part of routine clinical care.
Statistical methods
Summary statistics of the baseline populations of GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II are described using percentages or means (95% CIs), as appropriate. These included baseline demographics, vital signs, medical history, laboratory and imaging data, as well as baseline medical therapies. Comparison statistical tests are not calculated because the large sample sizes are likely to yield statistically significant differences that may or may not be clinically relevant.
For analyses of patients with new-onset AF, all cohorts were limited to patients diagnosed with AF within 6 weeks of enrollment. ORBIT-AF I included a small number of these patients, and so this cohort was excluded from this analysis of patients stratified by CHA 2 DS 2 -VASc.
Analyses of the data from GARFIELD-AF were performed by the Thrombosis Research Institute using SAS software (version 9.4; SAS Institute, Cary, NC). Analyses of the deidentified data from ORBIT-AF were performed by the Duke Clinical Research Institute using SAS software (version 9.3; SAS Institute, Cary, NC). The Thrombosis Research Institute and the GARFIELD-AF registry are supported by an unrestricted research grant from Bayer AG, Berlin, Germany. The ORBIT-AF registry is sponsored by Janssen Scientific Affairs, LLC, Raritan, NJ. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents.
Results

Patient demographics and clinical characteristics
The prospective population of GARFIELD-AF included 51,270 patients from 1,314 sites in 35 countries (including the United States). The ORBIT-AF I population included 10,132 patients from 174 US sites, and ORBIT-AF II included 11,602 patients from 242 US sites. Baseline characteristics of these 3 groups are shown in Table II . Patient age (mean 70-74 years) and female sex (about 42%-44%) were roughly balanced across the studies. However, there was variability in ethnic makeup across studies (63% of patients were white in GARFIELD-AF vs 85%-89% in ORBIT-AF I and II). Coronary artery disease was less common in the international GARFIELD-AF cohort (19% vs 36% and 27% for ORBIT-AF I and II, respectively). However, more than three-quarters of all patients had hypertension, and approximately one-fifth had diabetes in all studies. Patient characteristics, stratified by enrolling provider type (generalist vs cardiologist), are provided in the Supplemental Material (Table S1 ). Distributions of stroke (CHA 2 DS 2 -VASc) and bleeding (HAS-BLED) risk scores for each of the overall populations are shown in Figure 1 . These distributions were minimally skewed toward lower stroke risk for GARFIELD-AF compared with the ORBIT-AF cohorts. Overall, N85% of patients in both registry programs had high stroke risk (CHA 2 DS 2 -VASc ≥2), whereas high bleeding risk (HAS-BLED score ≥3) was present in 11% (GARFIELD-AF) to 24% (ORBIT-AF I) of patients.
Treatment of patients with new-onset AF
Among patients with AF diagnosed within 6 weeks, stroke prevention therapies are shown in Figure 2 . Use of NOACs, with and without antiplatelet therapies, increased over the study periods of both the GARFIELD-AF (3% NOAC in 2010 to 43% in 2016) and ORBIT-AF programs (2% NOAC in ORBIT-AF I in 2010 to 71% NOAC in ORBIT-AF II in 2016). Use of antiplatelet therapy alone for stroke prevention decreased over time in both programs (from 36% to 17% in GARFIELD-AF and from 18% to 8% in the ORBIT-AF program). Values are presented as n (%) or mean (95% CI), unless noted otherwise. TIA, Transient ischemic attack; CAD, coronary artery disease; CABG, coronary artery bypass grafting; PAD, peripheral arterial disease; CHF, congestive heart failure; NYHA, New York Heart Association; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Use of oral anticoagulation therapy (OAC) at baseline increased with increasing CHA 2 DS 2 -VASc score (Figure 3 ) (because of very low numbers of ORBIT-AF I patients in some categories, that cohort was excluded). Nearly half of patients with CHA 2 DS 2 -VASc score of 0 and new-onset AF received OAC (47% for GARFIELD-AF, 57% for ORBIT-AF II). Among patients with CHA 2 DS 2 -VASc ≥2, 69% and 87% of patients in GARFIED-AF and ORBIT-AF II, respectively, were treated with OAC. Among patients with new AF and CHA 2 DS 2 -VASc score ≥2, there was significant geographic variability in use of OAC across countries, from 31% to 93% in GARFIELD-AF and, across states within the United States, from 66% to 100% in ORBIT-AF II (Figure 4 ). For such patients in GARFIELD-AF enrolled from the United States, OAC use was 72% compared with 84% for the comparable ORBIT-AF US cohort.
Discussion
These analyses represent a global assessment of AF care, encompassing N70,000 patients from the GARFIELD-AF and ORBIT-AF I and II cohorts. Despite baseline differences in ethnic composition, overall comorbidities and risk profiles among patients with AF globally appear consistent across cohorts. Additionally, there have been major shifts in therapies for prevention of stroke in this population, including a move away from antiplatelet monotherapy and toward oral anticoagulation with NOACs around the world. However, the use of oral anticoagulation is common in patients with a low stroke risk (CHA 2 DS 2 -VASc score 0-1) but not consistently implemented in patients with a high stroke risk (CHA 2-DS 2 -VASc ≥2). Regional differences in treatment (both within the United States and between countries) may account for some of the undertreatment in higher-risk patients.
Our data add to those of several administrative claims analyses demonstrating anticoagulation underutilization for patients with AF. 8, 9 Although those studies capture large numbers of patients, claims data are primarily limited in the granularity of data available and usually isolated to single-country data sets. The present analyses also complement those of a worldwide epidemiology study assessing the global health burden and cost of AF. 2 Those investigators demonstrated increasing prevalence and associated disease morbidity from AF from 1990 to 2010. However, specific population characteristics were outside the scope of that analysis. Our data provide details of the AF population worldwide, as well as potential insights into the contributors to AF-associated health care expenditures. Both in the United States and around the world, patients with AF in our analysis were predominantly elderly, with high rates of cardiovascular risk factors as well as manifest cardiovascular disease.
We identified promising trends in oral anticoagulation for AF. Major, randomized clinical trials have demonstrated noninferiority or superiority of each NOAC compared with warfarin for stroke prevention, [10] [11] [12] [13] and a meta-analysis of these trials demonstrated very favorable risk-benefit profile for NOACs as a class. 14 Based on these data, shifting from warfarin to NOACs at the population level should decrease thromboembolic and bleeding rates for patients with AF. Additional analyses from these cohorts will examine whether such improvements are realized in clinical practice. These data also reflect a progressive shift away from antiplatelet therapy for stroke prevention in AF, as it is increasingly recognized to be of little benefit and not insignificant risk. [15] [16] [17] Our data demonstrated that for patients with new onset AF, nearly half of patients at low-risk of stroke were anticoagulated, yet only two-thirds of patients at high risk of stroke received appropriate OAC therapy. There may be several explanations for this paradox. The low-risk patients with new-onset AF may be receiving OAC in the setting of cardioversion, which could be appropriate for patients of any CHA 2 DS 2 -VASc score. However, risk-treatment paradoxes are well documented in local cohorts of AF patients, where the lowest-risk patients often receive aggressive therapy. 18 Physicians may perceive lower risk of causing harm in these patients, although their potential benefit is also lower. Our data demonstrate that this is not an isolated phenomenon. Among patients with CHA 2 DS 2 -VASc score of 1, OAC use rose to 55% in the GARFIELD-AF cohort and 65% in the ORBIT-AF II group. The appropriate target treatment rate is difficult to gauge, as there are few data to guide therapy in this "intermediate"-risk group-therefore, the latest US and European guidelines carry much weaker recommendations for these patients. 19, 20 Nevertheless, the overtreatment with anticoagulation of patients at very low risk of stroke (CHA 2 DS 2 -VASc = 0) would convey a significantly increased risk of bleeding in these patients, with likely little benefit in terms of thromboembolism prevention. In contrast, suboptimal implementation of anticoagulation prophylaxis in patients at the highest stroke risk (CHA 2 DS 2 -VASc ≥2) likely risks potentially preventable thromboembolic events.
Our analysis of regional variability in OAC use demonstrates significant heterogeneity and may account, in part, for the apparent undertreatment of high-risk patients. Furthermore, variability in treatment appears not only at the country level across the GARFIELD-AF study but also more locally at the state level in the ORBIT-AF program. This suggests that such differences in treatment result from local practice variation and not necessarily system-wide differences in management among locales, and represents an opportunity for education and improvement in quality of care for patients. As the burden of disease continues to increase, it remains imperative to appropriately implement treatments, targeted to local care delivery models, to improve outcomes and reduce health care costs worldwide.
Limitations
There may be sampling and/or selection biases in these observational, registry data. Additionally, there was a geographic imbalance in enrollment of patients, and some regions may be overrepresented, with the potential for regional differences in diagnoses and treatments. Lastly, differences in design and enrollment criteria must be considered when comparing GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II. Data were acquired via medical record review, and each study had its own data verification and auditing protocol.
Conclusions
Despite regional, ethnic, and other differences, patients with AF worldwide demonstrate similar risk profiles and manifest a significant burden of comorbid cardiovascular disease. The use of NOACs in patients with AF is increasing worldwide, with a concomitant decrease in the use of antiplatelet therapies. However, among new-onset AF, oral anticoagulation is commonly used in the lowest-risk patients, for unclear reasons. Furthermore, it is inconsistently prescribed to patients with a high risk of stroke. The significant geographic variability in the use of OAC represents an opportunity for education and implementation of consistent guideline-based recommendations.
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